Israel’s Galmed Wins South Korea Patent for New Liver Disease Combination Therapy

Jerusalem, 4 December, 2025 (TPS-IL) — Israeli biotech company Galmed Pharmaceuticals announced Thursday that South Korea has granted a new use patent for combining its lead drug candidate, Aramchol, with Rezdiffra, developed by U.S.-based Madrigal Pharmaceuticals, for treating liver fibrosis and MASH, a progressive liver disease.

The Ramat Gan–based firm said the patent extends Aramchol’s global protection to July 2042, adding to existing patents in the U.S., Europe and Canada.